Mechanism of Action: Calcium Chelating Activity

Drugs with Mechanism of Action: Calcium Chelating Activity

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Casper Pharma Llc	EDETATE CALCIUM DISODIUM	edetate calcium disodium	INJECTABLE;INJECTION	216435-001	May 3, 2023		RX	No	Yes
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes			Y
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes			Y
Meridian Bioscience	IDKIT:HP	citric acid; urea c-13	FOR SOLUTION, TABLET, FOR SOLUTION;ORAL	021314-001	Dec 17, 2002		RX	Yes	Yes

Calcium Chelating Activity Market Analysis and Financial Projection

The market for drugs with calcium chelating activity is expanding across pharmaceuticals, agriculture, and industrial sectors, fueled by technological innovation and rising demand for targeted therapies. Below is a detailed analysis of market dynamics and patent trends:

---

Market Dynamics

1. Growth Projections

   • The Diammonium EDTA market is projected to grow from USD 125.76 million (2024) to USD 174.61 million by 2030 at a 4.8% CAGR[1].
   • The Calcium Magnesium Chelating Resin Market is set to rise from USD 1.5 billion (2024) to USD 2.8 billion by 2032 (7.5% CAGR)[5].
   • The Hypercalcemia Treatment Market will surge from USD 22.6 billion (2025) to USD 52.3 billion by 2035 (8.7% CAGR), driven by cancer- and kidney disease-related hypercalcemia[7].

2. Key Drivers

   • Healthcare Demand: Aging populations and rising cardiovascular diseases (e.g., hypertension) propel the use of calcium channel blockers and chelation therapies[3][16].
   • Regulatory Approvals: Diammonium EDTA’s approval for food, cosmetics, and water treatment applications[1][13].
   • Technological Advances: Enhanced drug solubility via cyclodextrin complexes[8] and precision agriculture driving chelated mineral demand[10].

3. Sector-Specific Trends

   • Pharmaceuticals: Chelation therapy (e.g., EDTA) for heavy metal detoxification and cardiovascular disease shows promise, with trials like TACT2 exploring benefits for diabetic patients[11][16].
   • Agriculture: Chelated minerals (e.g., calcium, magnesium) improve nutrient delivery, supporting a USD 7.06 billion market by 2029[10].
   • Industrial: Calcium-magnesium resins dominate water treatment and chemical processes[5].

---

Patent Landscape

1. Innovative Formulations

   • Organic Calcium Chelates: CN101715961A patent uses industrial waste yeast to produce low-cost, eco-friendly chelates, reducing chemical residues[2].
   • Photosensitive Chelators: US4689432A and EP0292161A2 describe light-activated compounds that lose calcium affinity after illumination, enabling controlled drug release[9][14][15].

2. Drug Delivery & Applications

   • Cyclodextrin Complexation: Enhances solubility and bioavailability of water-insoluble drugs[8].
   • Heavy Metal Detox: Patents for bleomycin-cobalt conjugates (US4758421) target tumor imaging/therapy[9], while deferoxamine treats iron overload[11].

3. Strategic Patent Practices

   • Evergreening: Extending exclusivity via minor drug modifications (e.g., new formulations)[4].
   • Regional Variations: Stricter EMA regulations in Europe contrast with faster approvals in Asia-Pacific markets[7].

---

Challenges & Opportunities

• Regulatory Hurdles: Stringent EMA oversight and slow adoption of novel therapies in Europe[7].
• Safety Risks: EDTA’s potential to cause hypocalcemia requires careful dosing[16].
• Emerging Markets: Asia-Pacific’s rapid growth (9.2% CAGR for ashwagandha[3]) highlights untapped potential in precision agriculture and nutraceuticals[10].

---

Key Takeaways

• Calcium chelators are critical in addressing hypercalcemia, cardiovascular diseases, and environmental decontamination.
• Patent innovation focuses on cost reduction (e.g., yeast-based production[2]) and responsive drug mechanisms (e.g., light-sensitive chelators[14]).
• Market expansion hinges on regulatory adaptability and advancements in AI-driven drug development[4].

“Chelation therapy may represent a significant benefit for patients with diabetes and severe peripheral arterial disease, contributing to precision environmental medicine.” – Ravalli et al. (2022)[11]

References

1. https://virtuemarketresearch.com/report/diammonium-edta-market
2. https://patents.google.com/patent/CN101715961A/en
3. https://www.pharmiweb.com/press-release/2025-03-19/at-a-cagr-of-57-calcium-channel-blockers-market-rising-demand-for-cardiovascular-solutions-drug-innovation-through-2035-tmr-research
4. https://www.pharmafocuseurope.com/articles/drug-patents-shape-pharma-competition
5. https://www.marketresearchintellect.com/product/calcium-magnesium-chelating-resin-market/
6. https://patents.justia.com/patents-by-us-classification/514/836
7. https://www.futuremarketinsights.com/reports/hypercalcemia-treatment-market
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10156076/
9. https://patents.justia.com/patents-by-us-classification/424/DIG6
10. https://www.thebusinessresearchcompany.com/report/chelated-minerals-global-market-report
11. https://www.aetna.com/cpb/medical/data/200_299/0234.html
12. https://www.ijbcp.com/index.php/ijbcp/article/download/1517/1418/6245
13. https://datahorizzonresearch.com/chelating-agents-market-2718
14. https://patents.google.com/patent/US4689432A/en
15. https://patents.google.com/patent/EP0292161A2/en
16. https://www.ahajournals.org/doi/10.1161/JAHA.121.024648